Oracle is beefing up its health sciences suite (and its cloud-based solutions portfolio) with the acquisition of ClearTrial.
ClearTrial is a provider of cloud-based clinical trial operations applications intended to facilitate the planning, sourcing, and tracking of clinical projects while ensuring a more accurate and faster financial performance. Its customer base ranges from emerging companies to top-tier biopharmaceutical companies.
Neil de Crescenzo, senior vice president and general manager of Oracle Health Sciences, explained in a release that "biopharmaceutical, medical device and diagnostic companies, as well as contract research organizations are facing increasing pressure to deliver clinical development projects on time and within budget."
Thus, Oracle plans to simplify matters by combining its analytics resources with ClearTrial's applications to create a single clinical trial management offering from planning to payment for biopharmaceutical and medical device companies.
Financial terms of the agreement have not been disclosed. Until the transaction closes, Oracle and ClearTrial will continue to operate independently. The transaction is expected to close within the first half of 2012.
Not counting patent lawsuits and related legal matters, Oracle has been on a mini roll lately. Not only did the engineering giant recently post improved earnings for the third fiscal quarter, but it also bought up Taleo, an on-demand talent management software company, for $1.9 billion.
For reference, Taleo is a competitor to SuccessFactors, which was acquired by none other than SAP. Thus, that move made Oracle even stronger in the face of what CEO Larry Ellison described as "Oracle’s biggest competitor."
- Judge to Oracle-Google: Settle this Android flap
- HP, Oracle seek pretrial victories in Itanium battle
- Oracle shareholder sues over whistleblower case
- Oracle: Hardware business decelerates, cloud combat coming into view
- 2012 tech mergers to be pushed by cloud, social, says PwC